Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

View/ Open
Publication Date
2017-05Author
Dreno, B
Ribas, A
Larkin, J
Ascierto, PA
Hauschild, A
Thomas, L
Grob, J-J
Koralek, DO
Rooney, I
Hsu, JJ
McKenna, EF
McArthur, GA
Type
Journal Article
Metadata
Show full item recordCollections
Version of record
Subject
cobimetinib
MEK inhibition
melanoma
safety
Research team
Melanoma and Kidney Cancer
License start date
2017-05
Citation
ANNALS OF ONCOLOGY, 2017, 28 (5), pp. 1137 - 1144